RecruitingPhase 2NCT03936153
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Studying Diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Xynomic Pharmaceuticals, Inc.
- Principal Investigator
- Yuankai SHI, ProfCancer Institute and Hospital, Chinese Academy of Medical Sciences
- Intervention
- abexinostat(drug)
- Enrollment
- 170 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2027
Study locations (23)
- Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
- China-Japan Friendship Hospital, Beijing, China
- Peking University Third Hospital, Beijing, China
- West China Hospital, Sichuan University, Chengdu, China
- The First Affiliate Hospital of Dalian Medical University, Dalian, China
- Fujian Medical University Union Hospital, Fuzhou, China
- Fujian Provincial Cancer Hospital, Fuzhou, China
- Cancer Center of Guangzhou Medical University, Guangzhou, China
- Sun Yai-Sen Memorial Hospital, Sun Yai-Sen University, Guangzhou, China
- Zhejiang Cancer Hospital, Hangzhou, China
- The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China
- The First Hospital of Lanzhou University, Lanzhou, China
- Linyi Cancer Hospital, Linyi, China
- Nantong Tumor Hospital, Nantong, China
- Shanghai Jiao Tong University School Medicine, Shanghai, China
- +8 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03936153 on ClinicalTrials.govOther trials for Diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07365306Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07493109Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOPOu Bai, MD/PHD
- RECRUITINGPHASE2NCT07493148Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCLOu Bai, MD/PHD
- RECRUITINGPHASE3NCT07409428A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLHutchmed
- RECRUITINGPHASE2NCT07397832CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE3NCT07188558A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyLyell Immunopharma, Inc.
- RECRUITINGPHASE2NCT07499271Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07189065A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.